Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25354547 | 0.85 | OPRM1 (0.46) | CTSLCTSBCTSKCA1CA2 | |
| SCHEMBL21885808 | 0.83 | CA2 (0.49) | CTSLCTSBCTSKNAAACA1 | |
| SCHEMBL20672954 | 0.83 | CTSL (0.44) | CTSLCTSBCTSKNAAACA1 | |
| SCHEMBL24815593 | 0.83 | CA2 (0.49) | CTSLCTSBCTSKNAAACA1 | |
| SCHEMBL1873174 | 0.83 | CTSL (0.44) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL20595210 | 0.83 | CTSL (0.44) | CTSLCTSBCTSKNAAACA1 | |
| SCHEMBL24898491 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKNAAACA1 | |
| SCHEMBL29260419 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKNAAACA1 | |
| Potassium Ion SCHEMBL1868694 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL1868696 | 0.82 | CTSL (0.43) | CTSLCTSBCTSKNAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2023288254-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-2496575-B1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8466289-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466289-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466289-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| EP-2496575-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | Novartis AG (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| WO-2011054828-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054828-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | BRAF, KSR2, NRAS | CTSL 3558/4885CTSB 1022/4885CTSK 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.